[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612146":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":59,"collaborators":20,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":20,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Nabiqasim Industries (Pvt) Ltd","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"MASH targeted therapy","EXPERIMENTAL","MASH fibrosis stage 2 or 3",[13],"Drug: Resmetirom",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Resmetirom","1st FDA approved MASH therapy",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Hussain B Abidi, MBBS, MBA, CRCP","CONTACT","+923322583236","MDR.hussainabidi@gmail.com",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":20,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Liver transplant center, Holy family hospital","RECRUITING","Rawalpindi","Punjab Province","Pakistan","PK",{"type":36,"coordinates":37},"Point",[38,39],73.0479,33.59733,{"lat":39,"lon":38},[42,46,48,51,52,55,57],{"name":43,"role":24,"phone":44,"phoneExt":20,"email":45},"Shanila Akhter","+92 307 6738460","'shanilaakhter105@gmail.com'",{"name":47,"role":24,"phone":20,"phoneExt":20,"email":20},"Dr Anum Shakeel",{"name":49,"role":50,"phone":20,"phoneExt":20,"email":20},"Dr. Muhammad Umar","PRINCIPAL_INVESTIGATOR",{"name":47,"role":50,"phone":20,"phoneExt":20,"email":20},{"name":53,"role":54,"phone":20,"phoneExt":20,"email":20},"Dr. Bushra Khar","SUB_INVESTIGATOR",{"name":56,"role":54,"phone":20,"phoneExt":20,"email":20},"Dr Sadia Khan",{"name":58,"role":54,"phone":20,"phoneExt":20,"email":20},"Dr Tayyab Sb.",{"type":60,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100612146","phase-4-resmiterom-efficacy--safety-in-patients-with-mash-100612146",false,"NCT07249788","Resmiterom Efficacy & Safety in Patients With MASH","Clinical Evaluation of Safety and Efficacy of Resmiterom in Patients With MASH (Metabolic Dysfunction-Associated Steato-Hepatitis) A Prospective, Open-label, Interventional Study","REZMASH","Inclusion Criteria:\n\n* • At least one metabolic comorbidity (e.g., T2DM, obesity, dyslipidemia and hypertension)\n\n  * Clinical diagnosis of MASH using:\n\n    * LSM ≥ 8.5kpa And\u002For\n    * FAST score ≥0.67 And\u002For\n    * FibroScan CAP ≥ 275 dB\u002Fm And\u002For\n    * FIB-4 \\> 1.3\n\nExclusion Criteria:\n\n* • History of drug addiction and alcoholism\n\n  * Cirrhosis or decompensated liver disease\n  * Chronic viral hepatitis HBV, HCV)\n  * MACE including MI, Stroke, PE etc.\n  * Pregnant\u002Flactating women\n  * Concurrent use of other investigational drugs\n  * History of other liver diseases (viral, autoimmune, drug-induced, alcohol)\n  * Previous use of resmetirom in last 6 months\n  * Significant renal impairment (eGFR \\\u003C30)","ALL","18 Years","75 Years",{"count":73,"type":74},165,"ESTIMATED","INTERVENTIONAL",[77],"PHASE4","Phase 4 clinical trial study aims to further evaluate the safety and therapeutic efficacy of Resmetirom in Pakistani patients with fibroscan proven MASH.",[80],"MASH - Metabolic Dysfunction-Associated Steatohepatitis",[17,82,83,84],"MASH","Safety","Efficacy","2025-11-25",{"date":87,"type":88},"2025-12-03","ACTUAL",{"date":90,"type":88},"2025-10-17",{"date":92,"type":74},"2026-12-31",{"name":5,"class":6},1]